Figure 1
Prostate carcinoma-derived PDGF-D enhances bone reactions and intraosseous tumor growth. (a) Radiographic images of tibiae taken 17 weeks post-injection include a tibia injected with medium only (Injection control), one tibia injected with LNCaP-neo cells without tumor development (LNCaP-neo, no tumor), the only tibia of this group with intraosseous tumor growth (LNCaP-neo, w/tumor) and 8 tibiae bearing intraosseous LNCaP-PDGF-D tumors (mice B6, B7, B9, C6, C7, C8, C9, C10). The only LNCaP-neo tumor-bearing tibiae showed osteolytic appearance on its upper half with profound loss of bone trabecular and thinner bone cortex. LNCaP-PDGF-D bearing tibiae showed a mixed bone response. (b) Skeletal tumor incidence: number of mice with or without intraosseous tumor growth after injection with LNCaP-neo or LNCaP-PDGF-D cells (although 15 mice were injected in each group, two PDGF-D mice and one neo mouse died prematurely). (c) Skeletal tumor burden: tumor areas in the histological section of the entire tibia were calculated on the basis of the measurement of the corresponding areas in pixels2 as described in Materials and methods.
